Bifogade filer
Xintela 2022 Q2 EN
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.
Second quarter 2022 for the group
» Income amounted to TSEK 0 (0).
» Loss before tax totalled TSEK 18,942 (loss: 15,020).
» Loss per share was SEK 0.21 (loss: 0.17).
First half year 2022 for the group
» Income amounted to TSEK 0 (0).
» Loss before tax totalled TSEK 35,326 (loss: 26,699).
» Loss per share was SEK 0.40 (loss: 0.30).
Second quarter 2022 for the parent company
» Income amounted to TSEK 0 (0).
» Loss before tax totalled TSEK 11,547 (loss: 11,797).
» Loss per share was SEK 0.13 (loss: 0.13).
First half year 2022 for the parent company
» Income amounted to TSEK 0 (0).
» Loss before tax totalled TSEK 22,589 (loss: 20,842).
» Loss per share was SEK 0.26 (loss: 0.24).
» At June 30, 2022, the equity/assets ratio was -99 % (76).
Significant events in the second quarter of 2022
» Xintela starts clinical study of XSTEM® in knee osteoarthritis. (April 4, 2022)
» Targinta selects ADC-antibody TARG9 as drug candidate. (April 5, 2022)
» Targinta presents new preclinical data on TARG10 at the AACR Annual Meeting. (April 8, 2022)
» Xintela proposes Hans-Joachim Simons as new Board member. (May 3, 2022)
» Xintela publishes results showing that XSTEM repairs damaged joint cartilage in preclinical model. (May 9, 2022)
» Xintela is raising a capital raising that includes a fully guaranteed rights issue of SEK 44.6 million and an over-allotment
option of approximately SEK 10 million. (May 20, 2022)
» Targinta engages Abzena for the production of TARG9 and TARG10. (June 2, 2022)
» Targinta obtains patent grant in Japan. (June 8, 2022)
» Xintela announces timeline for capital raising. (June 15, 2022)
» Xintela publishes a prospectus due to the upcoming rights issue. (June 22, 2022)
Significant events after the end of the period
» Xintela receives approval for clinical study with XSTEM® on difficult-to-heal venous leg ulcers. (July 5, 2022)
» Xintela publishes the outcome of the rights issue and decides on a directed new issue of SEK 10 million. (June, 18 2022)
» Notice of Extraordinary General Meeting in Xintela AB (publ). (July, 18 2022)
» Per Norlén to step down as Targinta CEO. (August 2, 2022)
» Bulletin from the Extraordinary General Meeting in Xintela AB (publ). (August 3, 2022)
The complete interim report is available for download below and on the company’s website www.xintela.se/en/investors#reports